Evidence map›Paper›PMID 39324010›Full record

ArticleFrontiers in oncology2024

Heterogeneous SSTR2 target expression and a novel

Se Whee Sammy Park, Susanne Fransson, Fredrik Sundquist, Joachim N Nilsson, Per Grybäck, Sandra Wessman, Jacob Strömgren, Anna Djos, Henrik Fagman, Helene Sjögren and 8 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Fraction-dependent dose dynamics and clinical safety in high-risk neuroblastoma treated with [European journal of nuclear medicine and molecular imaging · 2026
    Trial
  2. Combination therapy strategies in engineeredCell communication and signaling : CCS · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Se Whee Sammy ParkDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Susanne FranssonDepartment of Laboratory Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Fredrik SundquistDepartment of Urology, Karolinska University Hospital, Stockholm, Sweden.
Joachim N NilssonDepartment of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.
Per GrybäckDepartment of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.
Sandra WessmanDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Jacob StrömgrenDepartment of Pediatric Radiology, Karolinska University Hospital, Stockholm, Sweden.
Anna DjosDepartment of Laboratory Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Henrik FagmanDepartment of Laboratory Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Helene SjögrenClinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg, Sweden.
Kleopatra GeorgantziDepartment of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Nikolas HeroldDepartment of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Per KognerDepartment of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Dan GranbergDepartment of Breast, Endocrine Tumors and Sarcomas, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
Mark N GazeDepartment of Oncology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.
Tommy MartinssonDepartment of Laboratory Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Kasper Karlsson *Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Jakob J E Stenman *Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this case report, we present the treatment outcomes of the first patient enrolled in the LuDO-N trial. The patient is a 21-month-old girl diagnosed with high-risk neuroblastoma (NB) and widespread skeletal metastasis. The patient initially underwent first-line therapy according to SIOPEN HRNBL-1 but was switched to second-line treatments due to disease progression, and she was finally screened for enrollment in the LuDO-N trial due to refractory disease. Upon enrollment, the patient received two rounds of the radiolabeled somatostatin analogue lutetium-177 octreotate (

Indexed as

177Lutetium-DOTATATEcase reportKIAA1649::BRAF gene fusionLuDO-N clinical trialmolecular radiotherapyneuroblastomatumor heterogeneity

Identifiers

PMID39324010
PMCPMC11422106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.